See more : Elevance Health Inc. (ELV) Income Statement Analysis – Financial Results
Complete financial analysis of RIV Capital Inc. (CNPOF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of RIV Capital Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Thor Explorations Ltd. (THXPF) Income Statement Analysis – Financial Results
- Kun Peng International Ltd. (KPEA) Income Statement Analysis – Financial Results
- Beijing Biostar Pharmaceuticals Co., Ltd. (2563.HK) Income Statement Analysis – Financial Results
- Focus Dynamics Group Berhad (0116.KL) Income Statement Analysis – Financial Results
- Yantai Shuangta Food Co., Ltd. (002481.SZ) Income Statement Analysis – Financial Results
RIV Capital Inc. (CNPOF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.rivcapital.com
About RIV Capital Inc.
RIV Capital Inc., formerly known as Canopy Rivers Inc., is a venture capital firm. The firm is a stage agnostic, with seed to sale, although it prefers to invest in series A to C rounds. It prefers to make investments in cannabis sector with focus on burgeoning marijuana companies and sectors like agriculture and food sciences, production, processing, pharmaceuticals and biotechnology, software and data, hardware, consumer products and accessories, wellness products, retail and distribution, and media and content. The firm also focuses on beverages, capsules and concentrates, edibles, dry flower / pre-rolls, vaporizers and hardware, pet products, and topicals. In agriculture and food sciences firm focuses in invest plant science, soil science, food science, animal science and environmental science. In production firm focuses in Indoor cultivation, greenhouse cultivation, outdoor cultivation, nursery cultivation and fermentation. In processing firm focuses in harvesting, extraction and purification, packaging, food and beverage processing and laboratory testing services. In pharmaceuticals and biotechnology firm focuses in pharmaceutical discovery and development, delivery method (ex: pill, soft gel, tincture), biosynthetic derived cannabinoids and other molecules, medical devices (ex: inhalers) and lab equipment. In consumer products and accessories firm focuses in edibles, beverages, inhalable, cosmetics and cannabis consumption accessories. In retail and distribution firm focuses in licensed brick and mortar retailers, pharmacies, online consumer marketplaces, delivery services, and others. The firm invests in opportunities globally. The firm prefers to invest in check sizes have ranged from CA$1 million ($0.71 million) to $40 million ($28.45 million), but more typical investment range is between CA$5 million ($3.6 million) to CA$10 million ($7.1 million). The firm is focused on making minority stake investments. Firm employ diverse investment structures including debt, preferred and common equity, and production-linked royalties. RIV Capital Inc. was founded on 2017 and is based in Toronto, Canada.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
---|---|---|---|---|---|---|---|
Revenue | 5.64M | 6.81M | 1.43M | 10.10M | 8.13M | 3.16M | 70.64M |
Cost of Revenue | 6.36M | 4.37M | 0.00 | 53.63M | -4.06M | -1.70M | 0.00 |
Gross Profit | -721.51K | 2.44M | 1.43M | -43.53M | 12.18M | 4.87M | 70.64M |
Gross Profit Ratio | -12.80% | 35.77% | 100.00% | -431.09% | 149.90% | 153.77% | 100.00% |
Research & Development | -10.73 | 0.00 | -21.19 | -8.52 | -2.83 | 2.15 | 0.00 |
General & Administrative | 0.00 | 17.97M | 7.76M | 6.09M | 13.02M | 22.32M | 2.41M |
Selling & Marketing | 0.00 | 351.00K | 0.00 | 0.00 | 0.00 | 560.89K | 7.86M |
SG&A | -8.66 | 20.50M | 7.76M | 6.09M | 13.02M | 22.32M | 10.28M |
Other Expenses | -63.77M | 1.22M | 561.96K | -1.13M | 969.69K | 236.62K | 1.29 |
Operating Expenses | 15.89M | 20.83M | 10.44M | 81.04M | 13.33M | 22.28M | 10.28M |
Cost & Expenses | 22.25M | 25.20M | 10.44M | 81.04M | 13.33M | 22.28M | -10.28M |
Interest Income | 0.00 | 653.00K | 1.51M | 12.75M | 4.86M | 1.63M | 0.00 |
Interest Expense | 11.09M | 17.22M | 5.78M | 22.17K | 25.37K | 0.00 | 81.60K |
Depreciation & Amortization | 22.25M | 2.00M | 58.01M | 37.79M | 36.81M | -5.32M | 43.82K |
EBITDA | -15.27M | -16.04M | -9.56M | -101.94M | -8.45M | -20.50M | -163.21K |
EBITDA Ratio | -270.84% | -235.70% | -670.26% | -1,009.54% | -103.95% | -647.80% | -0.23% |
Operating Income | 1.34M | -22.85M | -48.80M | -119.12M | -29.57M | 6.01M | 60.36M |
Operating Income Ratio | 23.77% | -335.63% | -3,421.16% | -1,179.66% | -363.77% | 189.94% | 85.45% |
Total Other Income/Expenses | 102.29M | -147.21M | -37.40M | -49.67M | -23.40M | 25.36M | -81.60K |
Income Before Tax | -15.27M | -182.18M | -52.20M | -120.63M | -28.62M | 6.25M | -43.82K |
Income Before Tax Ratio | -270.84% | -2,676.29% | -3,659.04% | -1,194.65% | -352.15% | 197.42% | -0.06% |
Income Tax Expense | -16.61M | -2.92M | -9.98M | -14.63M | -35.94K | 3.31M | -43.82K |
Net Income | -80.38M | -179.26M | -42.21M | -106.01M | -28.59M | 2.93M | -43.82K |
Net Income Ratio | -1,425.74% | -2,633.45% | -2,959.09% | -1,049.79% | -351.71% | 92.71% | -0.06% |
EPS | 126.73M | -1.09 | -0.30 | -0.75 | -0.15 | 0.02 | 0.00 |
EPS Diluted | 126.73M | -1.09 | -0.30 | -0.75 | -0.15 | 0.02 | 0.00 |
Weighted Avg Shares Out | -0.63 | 164.12M | 142.42M | 142.08M | 188.37M | 167.02M | 99.95M |
Weighted Avg Shares Out (Dil) | -0.63 | 164.12M | 142.42M | 142.08M | 188.37M | 167.02M | 99.95M |
RIV Capital Sets Date for Fourth Quarter and Fiscal Year 2023 Financial Results
The States Go Marching On
RIV Capital Inc. (CNPOF) Q2 2023 Earnings Call Transcript
RIV Capital Inc. (CNPOF) Q1 2023 Earnings Call Transcript
RIV Capital Sets Date for First Quarter 2023 Financial Results
RIV Capital Inc. (CNPOF) CEO Mark Sims on Q4 2022 Results - Earnings Call Transcript
RIV CAPITAL SETS DATE FOR THIRD QUARTER FISCAL YEAR 2022 FINANCIAL RESULTS
RIV Capital Inc. (CNPOF) CEO Narbé Alexandrian on Q2 2022 Results - Earnings Call Transcript
RIV Capital Announces Results of Annual General and Special Meeting of Shareholders
RIV Capital Receives ~$6.5 Million Upon Termination of PharmHouse's CCAA Proceedings
Source: https://incomestatements.info
Category: Stock Reports